Author(s): Olga Butylchenko, Dmitriy Ermakov, Dmitrii Babaskin


DOI: 10.52711/0974-360X.2022.00979   

Address: Olga Butylchenko1, Dmitriy Ermakov2*, Dmitrii Babaskin2
1Department of Phthisiopulmonology and Thoracic Surgery, I.M. Sechenov Fist Moscow State Medical University, Moscow, Russian Federation.
2Department of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
*Corresponding Author

Published In:   Volume - 15,      Issue - 12,     Year - 2022

Quinolones and their derivatives of the second to fourth generation (fluoroquinolones) are highly active antimicrobial agents. This research examines pharmacokinetic properties of fluoroquinolones in comparative aspect of their effect on pathogenic. Microflora of conjunctival cavity in children diagnosed with conjunctivitis and dacryocystitis. The study was carried out in 2020 in Ophthalmologic Polyclinics No. 1 (Moscow, the Russian Federation). The group comprised 200 children aged six years who were diagnosed with bacterial conjunctivitis and dacryocystitis. The composition of pathogenic microflora species and the effect of moxifloxacin and other fluoroquinolones on the sensitivity and resistance of microorganisms were analyzed using conjunctival scrapings. The presence of eight species of pathogenic microorganisms in the scrapings has been established. The majority of bacteria detected were gram-positive: St. epidermidis (59%) and St. aureus (21%), p = 0.05. Other types of microorganisms, including gram-negative E. coli, K. pneumonia, and St. saprophycus, were discovered 20 times (p=0.001 relative to St. epidermidis), 18 times (p = 0.001), and 15 times (p = 0.01) less frequently, accordingly. The levels of bacterial resistance were 13% for moxifloxacin, 16% for levofloxacin, and 21% for ciprofloxacin. Moxifloxacin monotherapy showed a 100% result. After five days of treatment, all patients demonstrated minimal values (0.5 and 0.1 points vs. 3.8 and 4.4 points at the beginning of treatment, p = 0.01) for two parameters (conjunctival hyperemia and sticky eye), the other three parameters were zero. Fourth-generation fluoroquinolone (moxifloxacin) has been shown to be highly effective against gram-positive Staphylococcus aureus bacteria.

Cite this article:
Olga Butylchenko, Dmitriy Ermakov, Dmitrii Babaskin. Pharmacokinetic properties of Fluoroquinolones in Comparative Aspect of their effect on Pathogenic microflora. Research Journal of Pharmacy and Technology 2022; 15(12):5800-6. doi: 10.52711/0974-360X.2022.00979

Olga Butylchenko, Dmitriy Ermakov, Dmitrii Babaskin. Pharmacokinetic properties of Fluoroquinolones in Comparative Aspect of their effect on Pathogenic microflora. Research Journal of Pharmacy and Technology 2022; 15(12):5800-6. doi: 10.52711/0974-360X.2022.00979   Available on:

1.    Alhufayti IA. Awareness of swimming pool conjunctivitis in Qassime. Research Journal of Science and Technology. 2017; 9(2): 229–30. doi:10.5958/2349-2988.2017.00040.7.
2.    Yıldırım S, Karakoç HN, Yaşar A, Köksal İ. Determination of levofloxacin, ciprofloxacin, moxifloxacin and gemifloxacin in urine and plasma by HPLC-FLD-DAD using pentafluorophenyl core-shell column: application to drug monitoring. Biomedical Chromatography. 2020; 34(10):e4925. doi:10.1002/bmc.4925.
3.    Sharma M, Nagori K, Soni S, Verma VS, Singh A. Herbal significance and home remedies to treat conjunctivitis: an overview. Research Journal of Topical and Cosmetic Sciences. 2014; 5(1):30–5. doi:10.5958/2321-5844.
4.    Täubel J, Prasad K, Rosano G, Ferber G, Wibberley H, Cole ST, Langenhoven LV, et al. Effects of the fluoroquinolones moxifloxacin and levofloxacin on the QT subintervals: sex differences in ventricular repolarization. The Journal of Clinical Pharmacology. 2020; 60(3):400–48. doi:10.1002%2Fjcph.1534.
5.    Yan A, Bryant EE. Quinolones. Treasure Island, FL: StatPearls Publishing; 2020.
6.    Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. Journal of Antimicrobial Chemotherapy. 2018; 73(6):1439–51. doi:10.1093/jac/dkx543.
7.    Altan F, Corum O, Yildiz R, Eser Faki H, Ider M, Ok M, Uney K. Intravenous pharmacokinetics of moxifloxacin following simultaneous administration with flunixin meglumine or diclofenac in sheep. Journal of Veterinary Pharmacology and Therapeutics. 2020; 43(2):108–14. doi:10.1111/jvp.12841.
8.    Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565–74. doi:10.1021%2Fbi5000564.
9.    Naeem A, Badshah SL, Muska M, Ahmad N, Khan K. The current case of quinolones: synthetic approaches and antibacterial activity. Molecules. 2016; 21(4):268. doi:10.3390/molecules21040268.
10.    Dave K, Qureshi A, Gopichandran L. Effects of earplugs and eye masks on perceived quality of sleep during night among patients in intensive care units. Asian Journal of Nursing Education and Research. 2015; 5(3):319–22. doi:10.5958/2349-2996.2015.00065.8.
11.    Arun Kumar SK, Kumar GA, Jayadevan J, Biju J. Knowledge and attitude on eye donation among selected rural and urban higher secondary school students, Ernakulam District. Asian Journal of Nursing Education and Research. 2016; 6(4):471–5. doi:10.5958/2349-2996.2016.00088.4.
12.    Verma R, Choudhary R. A descriptive study to assess the awareness and attitude regarding eye donation among nursing students of a selected college of nursing of District Mohali. Asian Journal of Nursing Education and Research. 2019; 9(1):69–74. doi:10.5958/2349-2996.2019.00014.4.
13.    Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC. The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs. 2019; 79(2):161–71. doi:10.1007/s40265-018-1043-y.
14.    Horcajada JP, Salata RA, Álvarez-Sala R, Nitu FM, Lawrence L, Quintas M, Cheng CY, et al. A Phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infectious Diseases. 2019; 7(1):21ofz514. doi:10.1093/ofid/ofz514.
15.    Jackson MA, Schutze GE. Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2016; 138(5):e20162706. doi:10.1542/peds.2016-2706.
16.    Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. The Journal of Clinical Pharmacology. 2016; 56(9):1060–75. doi:10.1002/jcph.715.
17.    Bisacchi GS, Hale MR. A “double-edged” scaffold: antitumor power within the antibacterial quinolone. Current Medicinal Chemistry. 2016; 23(6):520–77. doi:10.2174%2F0929867323666151223095839.
18.    Fedorowicz J, Sączewski J. Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules. Monatshefte für Chemie - Chemical Monthly. 2018; 149(7):1199–245. doi:10.1007/s00706-018-2215-x.
19.    Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anticancer agents: an underestimated truth. Biomedicine & Pharmacotherapy. 2019; 111:934–46. doi:10.1016/j.biopha.2018.12.119.
20.    Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum, Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2018; 125(9):1069–76. doi:10.1111/1471-0528.15119.
21.    Tyson GH, Li C, Hsu CH, Bodies-Jones S, McDermott PF. Diverse fluoroquinolone resistance plasmids from retail meat E. coli in the United States. Frontiers in Microbiology. 2019; 10:2826. doi:10.3389/fmicb.2019.02826.
22.    Ewig S, Hecker H, Suttorp N, Marre R, Welte, T. Moxifloxacin monotherapy versus ss-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. Journal of Infection. 2011; 62(3):218–25. doi:10.1016/j.jinf.2011.01.009.
23.    Garau J, Fritsch A, Arvis P, Read RC. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. Journal of Chemotherapy. 2010; 22(4):264–6. doi:10.1179/joc.2010.22.4.264.
24.    Litvinova TM, Kasimovskaya NA, Petrova VN, Volkova MM, Kalinina NV, Kochetkov IG, Kostina YA. The internal system for quality assessment of education results at a medical university. Electronic Journal of General Medicine. 2018; 15(4):em70. doi:10.29333/ejgm/93173.
25.    Juchenko LA, Kasimovskaia NA, Yakushina II. The medical genetic counseling and prevention of inborn and congenital pathology in the Russian Federation. Problemy Sotsial'noi Gigieny, Zdravookhraneniia i Istorii Meditsiny. 2015 Nov-Dec; 6:38–40.
26.    Gajanan GV, Pravin P, Adhikrao Y. Methods for evaluation of ocular insert with classification and uses in various eye diseases - a review. Asian Journal of Pharmacy Technology. 2017; 7(4):261–7. doi:10.5958/2231-5713.2017.00038.1.
27.    Miravitlles M, Llor C, Molina J, Naberan K, Cots JM, Ros F. Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life. International Journal of Chronic Obstructive Pulmonary Disease. 2010; 5:11-9. doi:10.2147%2Fcopd.s8732.
28.    Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, Starostin KM. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterology. 2020; 7(1):e000341.
29.    Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R, the PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory Research. 2010; 11:10. doi:10.1186/1465-9921-11-10.
30.    Mathew B. A study to assess the effectiveness of warm compress on level of dry eye among elderly adults in a selected old age home, Mangalore. International Journal of Nursing Education and Research. 2016; 4(1):15–23. doi:10.5958/2454–2660.2016.00003.X.
31.    Sahu T. An exploratory study to assess the knowledge and practices of mothers related to eye care of their children (3-6) years in an urban area of Ludhiana Punjab. International Journal of Nursing Education and Research. 2017; 5(4):421–4.
32.    Shukla P, SK Shukla, Bansal AK. Knowledge, attitude and practice study of tribal and nontribal people of a slum about eye health care. Research Journal of Pharmacology and Pharmacodynamics. 2011; 3(5):289–91. doi:10.5958 2321-5836.
33.    Lee S-R. A comprehensive study through training to prevent dry eye syndrome among mobile phone addicts. Research Journal of Pharmacy and Technology. 2018; 11(5):1796–9. doi:10.5958/0974-360X.2018.00334.7.
34.    Pavlov CS, Casazza G, Pavlova M, Nikolova D, Tsochatzis E, Liusina E, Gluud C. Ultrasonography for diagnosis of cirrhosis in people with alcoholic liver disease. Cochrane Library: Cochrane Reviews. 2016 Mar 2; 3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2.
35.    Safonov V. Comparison of LPO-AOS indices and biochemical composition of animal blood in biogeochemical provinces with different levels of selenium. Biological Trace Element Research, in press. 2021. doi:10.1007/s12011-021-02825-9.
36.    Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T. Low prevalence of fluoroquinolone-resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. International Journal of Medical Microbiology. 2011; 301(1):53–7. doi:10.1016/j.ijmm.2010.05.004.
37.    WHO. Treatment of tuberculosis: guidelines. 4th ed. Accessed 15 Jan 2021.
38.    Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrobial Agents and Chemotherapy. 2010; 54(11):4765–71. doi:10.1128/aac.00968-10.
39.    Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line H.pylori treatment. Digestive and Liver Disease. 2010; 42(2):110–14. doi:10.1016/j.dld.2009.05.013.
40.    Shah R, Bahauddin M, Islam R, Rahman M, Islam S, Arefin MK. Assessment of different strengths of Levofloxacin in the treatment of acute bacterial sinusitis. Science Journal of Medicine & Clinical Trial. 2013. Accessed 15 Jan 2021.
41.    Douros A, Grabowski K, Stahlmann R. Safety issues and drug-drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(1):25–39. doi:10.1517/17425255.2014.970166.
42.    U.S. Food & Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Accessed 15 Jan 2021.
43.    Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N. A review of moxifloxacin for the treatment of drug-susceptible tuberculosis. The Journal of Clinical Pharmacology. 2017; 57(11):1369–86. doi:10.1002/jcph.968.
44.    FDA Briefing Document. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 05, 2015. The benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis in patients who have chronic obstructive pulmonary disease (ABECB-COPD), and uncomplicated urinary tract infections (uUTI). Accessed 15 Jan 2021.
45.    Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Archives of Disease in Childhood. 2011; 96(9):874–80. doi:10.1136/adc.2010.208843.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available